COVID-19 Clinical Trials at SMH
Sarasota Memorial is proud to be among the selected hospitals participating in several national and multi-national clinical research trials focused on preventing and treating COVID-19, the disease caused by SARS-CoV-2 infection.
The SMH Clinical Research Team is currently enrolling eligible local participants for the following clinical trials:
- The study of Regeneron Pharmaceuticals' REGN-CoV-2 antibody cocktail for preventing COVID-19 in healthy adults.
- The study of the REGN-CoV-2 antibody cocktail for treating COVID-19 in hospitalized adults.
Enrollment in these trials is time-sensitive and limited to those who meet eligibility criteria.
For study specifics and eligibility questions, please call the SMH Clinical Research Center at 941-917-2225 (8am-3pm, Monday-Friday).
Regeneron REGN-CoV2 Antibody Cocktail
Sarasota Memorial is participating in multi-national clinical trials studying Regeneron’s dual-action, monoclonal antibody cocktail for the treatment and prevention of COVID-19.
Inpatient Treatment Trials: SMH is enrolling patients hospitalized with COVID-19 in randomized, placebo-controlled, double-blind clinical trials. Enrollment is time-sensitive. For study specifics and eligibility questions, please call the SMH Clinical Research Center at 941-917-2225 (8am-3pm, Monday-Friday).
Prevention Trial: SMH also is enrolling healthy adults in a randomized, placebo-controlled, double-blind clinical trial testing whether REGN-COV2 can prevent infection by the novel coronavirus that causes COVID-19. Enrollment is time-sensitive. To qualify, participants must have no symptoms and must have been in close contact (typically residing in the same household) with an infected person in a 96-hour window prior to receiving the REGN-CoV-2 antibody treatment or placebo. For more information and eligibility questions, please call the SMH Clinical Research Center at 941-917-2225 (8am-3pm, Monday-Friday).
Monoclonal Antibody Therapy
Sarasota Memorial is among a number of hospitals allocated monoclonal antibody therapy for non-hospitalized patients who have been diagnosed with a mild-to-moderate case of COVID-19 within the last 10 days, and have a high risk for severe disease or hospitalization. Click here to learn more.
Referrals: To refer a patient, physicians may call the monoclonal antibody infusion referral line at 941-262-0135 (from 8 am - 4:30 pm, Monday - Friday). Physicians can leave a voicemail after hours with physician name, patient name, patient date of borth, date of positive test, and best contact information for the patient.
** This webpage was last updated March 1, 2021.